OTCMKTS:TBUFF Tribute Pharmaceuticals Canada (TBUFF) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free TBUFF Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume50,100 shsAverage Volume71,826 shsMarket Capitalization$105.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Tribute Pharmaceuticals Canada alerts: Email Address Ad Porter & CompanyAmerica’s worst nightmare?What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.Click here to watch this bombshell exposé now. About Tribute Pharmaceuticals Canada Stock (OTCMKTS:TBUFF)Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.Read More Ad Porter & CompanyAmerica’s worst nightmare?What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.Click here to watch this bombshell exposé now. TBUFF Stock News HeadlinesMay 2, 2023 | yahoo.comWhen her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.April 27, 2023 | finance.yahoo.comMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONMarch 21, 2023 | mirror.co.ukKate Middleton pays tribute to 'incredibly sad' William as they mark St Patrick's DayOctober 16, 2022 | bbc.co.ukQueen Elizabeth II: Boats, tugs and ferries take part in Mersey tributeOctober 4, 2022 | mirror.co.ukLiz Truss pays tribute to Queen in 'passing of second Elizabethan age - speech in fullOctober 3, 2022 | bbc.co.ukFriends and colleagues pay tribute to Bill TurnbullSeptember 18, 2022 | investing.comTribute Pharmaceuticals Canada Inc (TRX)See More Headlines Receive TBUFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tribute Pharmaceuticals Canada and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2014Today5/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:TBUFF CUSIPN/A CIKN/A Webwww.tributepharma.ca Phone+1-905-8761118FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares113,720,000Free FloatN/AMarket Cap$105.76 million OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesArnold Tenney (Age 70)Chairman of the Board Robert Harris (Age 57)President, Chief Executive Officer, Director Scott Langille (Age 56)Chief Financial Officer, Director Janice M. Clarke (Age 52)Vice President - Finance and Administration Steven H. Goldman (Age 57)Independent Director John M. Gregory (Age 60)Independent Director John J. Kime (Age 70)Independent Director Francis Martin Thrasher (Age 61)Independent Director More Executives TBUFF Stock Analysis - Frequently Asked Questions How were Tribute Pharmaceuticals Canada's earnings last quarter? Tribute Pharmaceuticals Canada Inc. (OTCMKTS:TBUFF) posted its earnings results on Monday, March, 31st. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.01. The business had revenue of $2.90 million for the quarter. How do I buy shares of Tribute Pharmaceuticals Canada? Shares of TBUFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TBUFF) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tribute Pharmaceuticals Canada Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
